GORDIAN BIOTECHNOLOGY

A longevity-based start up with a novel screening platform to radically increase the efficiency of therapeutic development for complex diseases of ageing.

SAN FRANCISCO, USA

 
bill-oxford-gY-RMuSK1GI-unsplash.jpg

More about Gordian Biotechnology

NJF Capital presents Gordian Biotechnology. Gordian is motivated by the observation that the largest unmet medical needs, share two features: disease modifying treatments remain elusive, and their manifestation and progression are strongly age-dependent. These age-related diseases involve a complex, poorly understood interplay between cells and their physiological environment. Yet it is not known how to fully reproduce the diseased extracellular environment outside of the diseased organism itself. This reveals a significant limitation of current therapeutic screening methodologies, which rely on assays that take place ex vivo. Thus, Gordian has developed a discovery platform that makes in vivo experimentation the first step in the pre-clinical process, rather than the last. Gordian will use their high-throughput, in vivo screening technology to discover and develop novel targets and therapeutics that can meet large unmet needs in complex and age-related disease.